|
|
INDICATIONS AND USAGE
Attention Deficit Disorders, Narcolepsy
Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.
METADATE ER is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
Special Diagnostic Considerations
Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources.
Characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate-to-severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms.
|
DOSAGE AND ADMINISTRATION
Dosage should be individualized according to the needs and responses of the patient.
Adults
Methylphenidate Hydrochloride, USP Immediate-Release Tablets
Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.
Extended-Release Tablets
METADATE ER Tablets have a duration of action of approximately 8 hours. Therefore, the extended-release tablets may be used in place of the immediate-release tablets when the 8-hour dosage of METADATE ER Tablets corresponds to the titrated 8-hour dosage of the immediate-release tablets. METADATE ER Tablets must be swallowed whole and never crushed or chewed.
Children (6 Years And Over)
Methylphenidate hydrochloride tablets should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.
If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.
Methylphenidate Hydrochloride, USP Immediate-Release Tablets
Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
Extended-Release Tablets
METADATE ER Tablets have a duration of action of approximately 8 hours. Therefore, the extended-release tablets may be used in place of the immediate-release tablets when the 8-hour dosage of METADATE ER Tablets corresponds to the titrated 8-hour dosage of the immediate-release tablets. METADATE ER Tablets must be swallowed whole and never crushed or chewed.
If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug.
METADATE ER should be periodically discontinued to assess the child’s condition. Improvement may be sustained when the drug is either temporarily or permanently discontinued.
Drug treatment should not and need not be indefinite and usually may be discontinued after puberty.
|
HOW SUPPLIED
METADATE ER Tablets (methylphenidate hydrochloride extended-release tablets, USP) are available as follows:
10 mg: Oval, white, uncoated, unscored, debossed “561 MD”.
NDC 53014-593-07 Bottle of 100’s
20 mg: Round, white, uncoated, unscored, debossed “562 MD”.
NDC 53014-594-07 Bottle of 100’s
NOTE: METADATE ER Tablets are color-additive free.
Pharmacist
Dispense in a tight container as defined in the USP with a child-resistant closure.
Store at 20° - 25°C (68°-77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature]. Protect from moisture.
For Medical Information
Contact: Medical Affairs Department
Phone: (866) 822-0068
Fax: (770) 970-8859
Manufactured for
UCB, Inc.
Smyrna, GA 30080
Rev. 6E 08/2008
METADATE is a registered trademark of the UCB Group of companies
© 2008, UCB, Inc., Smyrna, GA 30080 All rights reserved. Printed in U.S.A.
|
|
|
|
-- advertisement --
|
